Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3917853rdf:typepubmed:Citationlld:pubmed
pubmed-article:3917853lifeskim:mentionsumls-concept:C0332835lld:lifeskim
pubmed-article:3917853lifeskim:mentionsumls-concept:C1882899lld:lifeskim
pubmed-article:3917853lifeskim:mentionsumls-concept:C0002260lld:lifeskim
pubmed-article:3917853lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:3917853lifeskim:mentionsumls-concept:C0596263lld:lifeskim
pubmed-article:3917853lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:3917853pubmed:issue2lld:pubmed
pubmed-article:3917853pubmed:dateCreated1985-2-28lld:pubmed
pubmed-article:3917853pubmed:abstractTextInhibitory effects of alpha-difluoromethylornithine (DFMO) on urinary bladder carcinogenesis were examined using the heterotopically transplanted rat urinary bladder (HTB) model. Male Fischer rats with an HTB were arbitrarily divided into four groups. Group 1 rats received into the HTBs 0.25 mg of N-methyl-N-nitrosourea (MNU) once a week for 3 weeks, followed by instillation twice a week of 0.5 ml of 2% DFMO dissolved in normal rat urine. Group 2 rats received the same amount of MNU, followed by instillation of urine without DFMO. Group 3 rats received a single dose of 0.25 mg of MNU, followed by instillation twice a week of urine containing 2% DFMO. Group 4 rats were treated as those in Group 3 but without DFMO. At 8, 14, and 20 weeks after the last MNU administration, urothelial polyamine levels and [3H] thymidine incorporation by the urothelium of HTBs were determined in nine rats of Groups 1 and 2. The remaining animals of Groups 1 and 2 were killed 25 weeks after the beginning of MNU injection, while those of Groups 3 and 4, 30 weeks after the MNU treatment. The contents of 3 polyamines (putrescine, spermidine, and spermine) in urothelial cells were significantly lower in Group 1 as compared with Group 2. The incidences of carcinoma were significantly lower in the groups treated with DFMO (p less than 0.001, Group 1 versus Group 2; p less than 0.005, Group 3 versus Group 4). These observations indicate that administration of DFMO inhibits (or retards) bladder carcinogenesis in HTBs. A possible mechanism for this effect is suppression of polyamine biosynthesis and proliferation of bladder epithelial cells.lld:pubmed
pubmed-article:3917853pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3917853pubmed:languageenglld:pubmed
pubmed-article:3917853pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3917853pubmed:citationSubsetIMlld:pubmed
pubmed-article:3917853pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3917853pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3917853pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3917853pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3917853pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3917853pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3917853pubmed:statusMEDLINElld:pubmed
pubmed-article:3917853pubmed:monthFeblld:pubmed
pubmed-article:3917853pubmed:issn0008-5472lld:pubmed
pubmed-article:3917853pubmed:authorpubmed-author:OyasuRRlld:pubmed
pubmed-article:3917853pubmed:authorpubmed-author:HommaYYlld:pubmed
pubmed-article:3917853pubmed:authorpubmed-author:SeidenfeldJJlld:pubmed
pubmed-article:3917853pubmed:authorpubmed-author:OzonoSSlld:pubmed
pubmed-article:3917853pubmed:authorpubmed-author:NumataIIlld:pubmed
pubmed-article:3917853pubmed:issnTypePrintlld:pubmed
pubmed-article:3917853pubmed:volume45lld:pubmed
pubmed-article:3917853pubmed:ownerNLMlld:pubmed
pubmed-article:3917853pubmed:authorsCompleteYlld:pubmed
pubmed-article:3917853pubmed:pagination648-52lld:pubmed
pubmed-article:3917853pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:3917853pubmed:meshHeadingpubmed-meshheading:3917853-...lld:pubmed
pubmed-article:3917853pubmed:meshHeadingpubmed-meshheading:3917853-...lld:pubmed
pubmed-article:3917853pubmed:meshHeadingpubmed-meshheading:3917853-...lld:pubmed
pubmed-article:3917853pubmed:meshHeadingpubmed-meshheading:3917853-...lld:pubmed
pubmed-article:3917853pubmed:meshHeadingpubmed-meshheading:3917853-...lld:pubmed
pubmed-article:3917853pubmed:meshHeadingpubmed-meshheading:3917853-...lld:pubmed
pubmed-article:3917853pubmed:meshHeadingpubmed-meshheading:3917853-...lld:pubmed
pubmed-article:3917853pubmed:meshHeadingpubmed-meshheading:3917853-...lld:pubmed
pubmed-article:3917853pubmed:meshHeadingpubmed-meshheading:3917853-...lld:pubmed
pubmed-article:3917853pubmed:meshHeadingpubmed-meshheading:3917853-...lld:pubmed
pubmed-article:3917853pubmed:meshHeadingpubmed-meshheading:3917853-...lld:pubmed
pubmed-article:3917853pubmed:meshHeadingpubmed-meshheading:3917853-...lld:pubmed
pubmed-article:3917853pubmed:year1985lld:pubmed
pubmed-article:3917853pubmed:articleTitleInhibition of carcinogenesis by alpha-difluoromethylornithine in heterotopically transplanted rat urinary bladders.lld:pubmed
pubmed-article:3917853pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3917853pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed